Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Phase I trial of cabozantinib and nivolumab ± CBM588 in metastatic RCC

Hedyeh Ebrahimi, MD, MPH, City of Hope Comprehensive Cancer Center, Duarte, CA, discusses updated outcomes from a Phase I trial (NCT05122546) of cabozantinib and nivolumab with or without CBM588, a live bacterial product, in metastatic renal cell carcinoma (mRCC). The addition of CBM588 was associated with higher response rates and prolonged progression-free survival compared to cabozantinib and nivolumab alone. The combination maintained a manageable safety profile, with no new safety signals observed. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.